CASI Pharmaceuticals (CASI)
CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the Greater China market leveraging the Company’s China-based regulatory and commercial competencies and its global drug development expertise. The Company’s operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd. (“CASI China”), which is located in Beijing, China. The Company has built a commercial team of over 70 hematology and oncology sales and marketing specialists based in China.

Company profile
Ticker
CASI
Exchange
Website
CEO
Wei-Wu He
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Ginkgo Bioworks • Bio-Techne • Denali Therapeutics ...
Former names
ENTREMED INC
SEC CIK
Corporate docs
Subsidiaries
CASI Pharmaceuticals (China) Co., Ltd, a company of limited • Beijing Zhongbai Biotechnology Co., Ltd. • Miikana Therapeutics, Inc. • CASI Biopharmaceuticals (WUXI) Co., Ltd., a company of limited • CASI Pharmaceuticals (WUXI) Co., Ltd., a company of limited • CASI Pharmaceuticals (Hainan) Co., Ltd., a company of limited ...
IRS number
581959440
CASI stock data
News

41 Stocks Moving In Monday's Mid-Day Session
16 May 22
30 Stocks Moving in Monday's Pre-Market Session
16 May 22
HC Wainwright & Co. Maintains Buy on CASI Pharmaceuticals, Lowers Price Target to $3
16 May 22
CASI Pharmaceuticals: Q1 Earnings Insights
12 May 22
Recap: CASI Pharmaceuticals Q1 Earnings
12 May 22
Press releases
CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2022 FINANCIAL RESULTS
12 May 22
CASI PHARMACEUTICALS TO REPORT FIRST QUARTER 2022 FINANCIAL RESULTS AND HOST CONFERENCE CALL MAY 12, 2022
2 May 22
CASI PHARMACEUTICALS STATEMENT ON STATUS UNDER HOLDING FOREIGN COMPANIES ACCOUNTABLE ACT
1 Apr 22
CASI PHARMACEUTICALS ANNOUNCES FULL-YEAR 2021 FINANCIAL RESULTS AND FOURTH QUARTER 2021 EVOMELA® REVENUE
28 Mar 22
CASI PHARMACEUTICALS TO REPORT FOURTH QUARTER AND YEAR END 2021 FINANCIAL RESULTS AND HOST CONFERENCE CALL MARCH 28, 2022
23 Mar 22
Analyst ratings and price targets
Investment data
Securities sold
Number of investors
Calendar
12 May 22
17 May 22
31 Dec 22
Financial summary
Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 29.26M | 29.26M | 29.26M | 29.26M | 29.26M | 29.26M |
Cash burn (monthly) | 3.15M | 3.24M | 2.8M | 2.89M | 1.41M | 1.92M |
Cash used (since last report) | 4.89M | 5.03M | 4.35M | 4.49M | 2.2M | 2.99M |
Cash remaining | 24.37M | 24.23M | 24.91M | 24.77M | 27.06M | 26.27M |
Runway (months of cash) | 7.7 | 7.5 | 8.9 | 8.6 | 19.2 | 13.7 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Dec 21 | Alexander A Zukiwski | Employee Stock Option Common Stock | Grant | Dispose A | No | No | 0.87 | 500,000 | 435K | 500,000 |
18 Nov 21 | He Wei-Wu | Common Stock | Buy | Acquire P | No | No | 0.98 | 200,000 | 196K | 5,558,472 |
17 Nov 21 | He Wei-Wu | Common Stock | Buy | Acquire P | No | No | 0.99 | 200,000 | 198K | 5,362,569 |
19 Aug 21 | He Wei-Wu | Common Stock | Buy | Acquire P | No | No | 1.26 | 180,000 | 226.8K | 5,163,994 |
18 Aug 21 | He Wei-Wu | Common Stock | Buy | Acquire P | No | No | 1.29 | 300,000 | 387K | 4,983,994 |
24 Jul 21 | Zhang Larry | Employee Stock Option Common Stock | Grant | Dispose A | No | No | 1.28 | 800,000 | 1.02M | 800,000 |
15 Jun 21 | Salisbury Franklin Cary jr | Stock Option Common Stock | Grant | Acquire A | No | No | 1.65 | 110,459 | 182.26K | 110,459 |
Institutional ownership, Q4 2021
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0 |
Total shares | 0 |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Financial report summary
?Management Discussion
- Product sales consist of sales of EVOMELA® that launched during August 2019. Revenue was $9.0 million for the three months ended March 31, 2022 compared to $5.7 million for the three months ended March 31, 2021. Revenues increased by 58% in the first quarter of 2022 as compared to same quarter in 2021 due to the continued growth in EVOMELA® sales.
- Lease income consists primarily of an equipment lease with Juventas (a related party). Lease income was $37,000 and $36,000, respectively, for the three months ended March 31, 2022 and 2021.
- Cost of revenues consists primarily of the cost of inventories of EVOMELA® and sales-based royalties related to the sale of EVOMELA®.
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
accredited, America, analogy, approximately, Assistance, ASU, attributable, auditor, Barcelona, bid, bill, billion, BioHealth, CDE, Center, certainty, CNCT, consecutive, create, CRPCGIT, CTA, cytotoxic, enhance, esteve, expenditure, FASB, firm, follicular, founder, France, Genetic, Group, guidance, haemopoietic, headquartered, Healthcare, HFCAA, HGRAC, IA, inspect, inspection, issuance, led, mantle, manufactory, marginal, notify, passed, PCAOB, permitted, PK, PRC, prohibit, prohibited, prohibition, prospectively, provision, Recommended, registered, rely, repurchase, repurchased, restriction, retrospectively, revision, run, satisfy, scientific, Senate, shutdown, Spain, stage, submit, submitted, suggested, terminated, threat, Topic, unanticipated, unpaid, withdrawal
Removed:
accessible, Accretion, achievement, acquire, activity, addressing, adult, Aid, allocated, Allocation, alternate, annualized, annum, appointed, arise, arrangement, Article, assume, attend, audited, automatically, award, bankruptcy, bear, behalf, BioCheck, book, Branch, build, California, call, candidate, capitalized, carrier, CCA, Chartwell, CITIC, cloud, collected, combined, comparable, compensating, confidence, considerable, consideration, consisting, consolidation, constraint, continuing, controlling, converted, conveyed, Corporation, CRGK, customer, data, decline, deemed, delayed, depend, derecognized, derived, designated, director, disbursed, discontinued, disease, disposal, dissolution, distancing, divided, dividend, dosing, Dr, duty, Electronic, eliminated, embedded, enactment, Engineering, enrollment, Enterprise, entitled, entity, estimable, estimation, evidenced, execution, expired, factor, factory, federal, fixed, Flexibility, forgiven, framework, funded, gain, granted, guarantee, guaranteed, guard, Guokang, HCW, health, hierarchical, highest, holder, Huicun, identification, Incentive, increasing, Industry, infection, influence, initially, initiation, institution, instrument, Jintou, lab, large, lead, lender, life, line, liquidation, loan, lowest, mandated, mandatorily, mandatory, manufacturer, marketed, MaxCyte, maximum, measuring, meet, member, method, microtubule, Miikana, monthly, negatively, newly, observability, observer, occur, occurred, orderly, ordinary, Organization, organized, ownership, parent, participant, partnership, pattern, paused, Paycheck, percent, performance, permanent, Ph, pharmacology, Philadelphia, planned, PPP, PPPFA, predicted, preference, preferred, presentation, prioritization, priority, privately, progressed, prolongation, promissory, protocol, put, quarantine, radiotherapeutic, rational, read, receive, receiving, recognition, recognize, record, recruitment, redeem, Regulation, relapse, relevant, Relief, remain, represented, requisite, resolved, retain, retroactive, reverse, review, round, Rx, SBA, security, segment, SEK, selected, service, settle, settled, shareholder, sheet, shipment, site, social, space, speak, split, state, stated, stipulated, stipulation, stockholder, subscribe, subsequently, subsidiary, substantive, summary, susceptible, systematic, temporary, tranche, transaction, transfer, transferred, travel, treat, type, unadjusted, unfold, unit, unsecured, vendor, vesting, voting, yield
Current reports
8-K
Casi Pharmaceuticals Announces First Quarter 2022 Financial Results
12 May 22
8-K
Other Events
2 May 22
8-K
Casi Pharmaceuticals Announces Full-year 2021 Financial Results and Fourth Quarter 2021 Evomela® Revenue
28 Mar 22
8-K
Casi Pharmaceuticals Announces Renewal of Exclusive Distribution Agreement for Evomela® In China
4 Mar 22
8-K
Casi Pharmaceuticals Announces Preliminary Fourth Quarter and Full-year 2021 Revenues and Provides Business Updates
16 Feb 22
8-K
Casi Pharmaceuticals, Receives Nasdaq Deficiency Notice
3 Jan 22
8-K
Casi Pharmaceuticals Announces Stock Repurchase Program
17 Dec 21
8-K
Departure of Directors or Certain Officers
10 Dec 21
8-K
Casi Pharmaceuticals Announces Third Quarter 2021 Financial Results
12 Nov 21
8-K
Entry into a Material Definitive Agreement
29 Oct 21
Registration and prospectus
424B5
Prospectus supplement for primary offering
29 Oct 21
S-8
Registration of securities for employees
13 Aug 21
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Aug 21
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Aug 21
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Aug 21
424B5
Prospectus supplement for primary offering
24 Mar 21
424B5
Prospectus supplement for primary offering
23 Mar 21
S-3
Shelf registration
20 Nov 20
424B5
Prospectus supplement for primary offering
23 Jul 20
424B5
Prospectus supplement for primary offering
21 Jul 20
Other
EFFECT
Notice of effectiveness
3 Dec 20
CORRESP
Correspondence with SEC
29 Nov 20
UPLOAD
Letter from SEC
26 Nov 20
CT ORDER
Confidential treatment order
20 Aug 19
CT ORDER
Confidential treatment order
6 Jun 19
EFFECT
Notice of effectiveness
30 Nov 18
CORRESP
Correspondence with SEC
26 Nov 18
UPLOAD
Letter from SEC
20 Nov 18
EFFECT
Notice of effectiveness
9 Aug 18
CORRESP
Correspondence with SEC
5 Aug 18
Ownership
SC 13G/A
CASI Pharmaceuticals / Consonance Capital Management ownership change
14 Feb 22
SC 13G/A
CASI Pharmaceuticals / FEDERATED HERMES ownership change
14 Feb 22
4
CASI Pharmaceuticals / Alexander A Zukiwski ownership change
6 Dec 21
SC 13D/A
CASI Pharmaceuticals / He Wei-Wu ownership change
23 Nov 21
4
CASI Pharmaceuticals / Wei-Wu He ownership change
19 Nov 21
4
CASI Pharmaceuticals / Wei-Wu He ownership change
20 Aug 21
4
CASI Pharmaceuticals / Larry Zhang ownership change
26 Jul 21
4
CASI Pharmaceuticals / Quan Zhou ownership change
16 Jun 21
4
CASI Pharmaceuticals / Yue Alexander Wu ownership change
16 Jun 21
4
CASI Pharmaceuticals / RAJESH C MD SHROTRIYA ownership change
16 Jun 21
Transcripts
2022 Q1
Earnings call transcript
12 May 22
2021 Q4
Earnings call transcript
28 Mar 22
2021 Q3
Earnings call transcript
13 Nov 21
2021 Q2
Earnings call transcript
13 Aug 21
2021 Q1
Earnings call transcript
19 May 21
2020 Q3
Earnings call transcript
10 Nov 20
2020 Q2
Earnings call transcript
10 Aug 20
Reddit threads
Daily Discussion Thread - May 12th, 2022
12 May 22
Daily Discussion Thread - May 11th, 2022
11 May 22
Just grit your teeth and get through it
9 May 22
Charlie Munger: Should You Invest In China?
8 May 22
Daily Discussion Thread - March 28th, 2022
28 Mar 22
Most Anticipated Earnings Releases for the week beginning March 28th, 2022
26 Mar 22
Wall Street Week Ahead for the trading week beginning March 28th, 2022
25 Mar 22
Now that most penny stocks dropped quite a bit, which ones are worth taking a look at?
20 Feb 22
What are your top 5 holdings?
3 Dec 21
Daily General Discussion and spitballin thread - November 30, 2021
30 Nov 21